PubRank

Giuseppe Viale

Author PubWeight™ 355.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010 14.41
2 Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013 12.57
3 A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003 11.93
4 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007 8.41
5 Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006 8.38
6 Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013 6.79
7 Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014 6.76
8 Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011 6.11
9 Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013 5.67
10 Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010 5.57
11 CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012 5.27
12 Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2014 5.18
13 Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005 4.86
14 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010 4.38
15 Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013 4.21
16 Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010 3.98
17 Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004 3.87
18 Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010 3.61
19 Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst 2013 3.35
20 Breast cancer. Lancet 2005 3.27
21 Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A 2009 3.10
22 Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009 2.98
23 NUMB controls p53 tumour suppressor activity. Nature 2008 2.91
24 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010 2.72
25 HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012 2.68
26 Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012 2.64
27 Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2013 2.54
28 An international Ki67 reproducibility study. J Natl Cancer Inst 2013 2.46
29 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004 2.46
30 Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2007 2.44
31 Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006 2.36
32 Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast 2006 2.36
33 A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003 2.25
34 Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012 2.22
35 Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008 2.14
36 Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010 2.14
37 International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007 2.02
38 Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. Gut 2012 2.02
39 Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2006 1.99
40 Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010 1.97
41 Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007 1.97
42 The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2008 1.96
43 Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 2006 1.89
44 The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011 1.79
45 Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005 1.73
46 EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging 2009 1.68
47 Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2007 1.66
48 Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003 1.63
49 How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One 2012 1.61
50 Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2009 1.61
51 Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010 1.54
52 Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010 1.51
53 Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"? Breast 2013 1.51
54 Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009 1.50
55 Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer 2004 1.48
56 Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol 2004 1.48
57 Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009 1.47
58 Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005 1.47
59 Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005 1.45
60 Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 2013 1.45
61 Management of triple negative breast cancer. Breast 2010 1.43
62 Breast cancer classification: time for a change. J Clin Oncol 2009 1.43
63 Axillary lymph node involvement in women with breast cancer: does it depend on age? Clin Breast Cancer 2010 1.39
64 Reciprocal repression between P53 and TCTP. Nat Med 2011 1.35
65 Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 2006 1.32
66 Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 2013 1.30
67 Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2008 1.29
68 Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 2009 1.28
69 The surgical margin status after breast-conserving surgery: discussion of an open issue. Breast Cancer Res Treat 2009 1.25
70 Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2008 1.24
71 Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol 2007 1.23
72 Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg 2008 1.20
73 Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014 1.20
74 Ultrasound-guided vacuum-assisted core breast biopsy: experience with 406 cases. Breast Cancer Res Treat 2006 1.20
75 The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics 2009 1.19
76 Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol 2004 1.18
77 An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One 2011 1.17
78 Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 2004 1.16
79 The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med 2011 1.16
80 Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. Proc Natl Acad Sci U S A 2010 1.15
81 The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008 1.14
82 Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat 2011 1.14
83 Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 2012 1.11
84 Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer 2004 1.11
85 Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer 2005 1.10
86 Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat 2006 1.09
87 Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis. J Cutan Pathol 2009 1.08
88 Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat 2014 1.08
89 Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003 1.07
90 Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011 1.07
91 Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 2008 1.06
92 Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 2003 1.06
93 Ectopic breast tissue as a possible cause of false-positive axillary sentinel lymph node biopsies. Am J Surg Pathol 2003 1.05
94 Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 2012 1.05
95 Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002 1.04
96 Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol 2005 1.03
97 Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. Breast J 2009 1.02
98 Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat 2013 1.02
99 Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association. Am J Surg Pathol 2006 1.01
100 K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004 1.01
101 A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. Eur J Cancer 2010 1.00
102 A primary pure yolk sac tumor of the lung exhibiting CDX-2 immunoreactivity and increased serum levels of alkaline phosphatase intestinal isoenzyme. Int J Surg Pathol 2006 1.00
103 Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 2011 0.99
104 Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res 2012 0.98
105 Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res 2010 0.98
106 Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother Pharmacol 2007 0.98
107 Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study. Lung Cancer 2008 0.97
108 The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 2005 0.97
109 p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002 0.96
110 Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2011 0.96
111 The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. Breast Cancer Res Treat 2005 0.96
112 Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma. Eur Radiol 2005 0.96
113 HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007 0.95
114 Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer 2012 0.94
115 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study. Clin Cancer Res 2007 0.94
116 Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer 2003 0.93
117 The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. Acta Oncol 2011 0.93
118 Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations. World J Surg Oncol 2012 0.93
119 Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin Breast Cancer 2010 0.93
120 Pirin inhibits cellular senescence in melanocytic cells. Am J Pathol 2011 0.92
121 Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 2003 0.91
122 Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast 2009 0.91
123 Prediction of cancer outcome with microarrays. Lancet 2005 0.91
124 Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann Surg Oncol 2005 0.91
125 Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012 0.90
126 Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma. Arch Surg 2002 0.90
127 Cytogical features of calcifying epithelial odontogenic tumor (Pindborg tumor) with abundant cementum-like material. Virchows Arch 2002 0.90
128 CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch 2003 0.90
129 Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol 2008 0.89
130 A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. J Proteomics 2011 0.89
131 A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006 0.89
132 Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat 2008 0.89
133 Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging 2010 0.89
134 Sentinel node detection in pre-operative axillary staging. Eur J Nucl Med Mol Imaging 2004 0.88
135 Follicular dendritic cell sarcoma of the breast. Virchows Arch 2002 0.88
136 Sentinel node biopsy in male breast cancer. Nucl Med Commun 2004 0.88
137 Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. Oncologist 2010 0.88
138 Search for loss of heterozygosity and mutation analysis of KRIT1 gene in CCM patients. Am J Med Genet A 2004 0.87
139 Branchiogenic carcinoma--conceptual or true clinico-pathological entity? Cancer Treat Rev 2005 0.87
140 Surgical outcomes after total mesorectal excision for rectal cancer. J Surg Oncol 2006 0.87
141 Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 2002 0.87
142 Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: Case 2. Plasma cell myeloma coexisting with metastatic breast carcinoma in the bone marrow. J Clin Oncol 2005 0.87
143 Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. Hum Pathol 2003 0.87
144 Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy. Virchows Arch 2005 0.87
145 Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer. Angiogenesis 2014 0.87
146 p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest 2002 0.87
147 The clinical relevance of micropapillary carcinoma of the breast: a case-control study. Histopathology 2013 0.87
148 Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. BMC Cancer 2010 0.86
149 Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol 2003 0.86
150 Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 2004 0.86
151 Salivary gland choristoma of breast. Breast J 2011 0.86
152 Conservative treatment of breast cancer: its evolution. Breast Cancer Res Treat 2005 0.86
153 Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs 2009 0.86
154 Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2014 0.85
155 Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer 2008 0.85
156 Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 2011 0.85
157 Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. Breast 2013 0.85
158 Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 2008 0.85
159 Intravascular papillary endothelial hyperplasia of the renal vein. Int J Surg Pathol 2009 0.85
160 Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology 2009 0.85
161 Identification of a novel KRIT1 mutation in an Italian family with cerebral cavernous malformation by the protein truncation test. J Neurol Sci 2003 0.85
162 CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch 2004 0.84
163 Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. Arch Gynecol Obstet 2013 0.84
164 Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. J Pathol 2003 0.84
165 Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol 2013 0.84
166 Pirin delocalization in melanoma progression identified by high content immuno-detection based approaches. BMC Cell Biol 2010 0.84
167 Basaloid cell carcinoma of the prostate. Virchows Arch 2003 0.84
168 Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. J Pathol 2012 0.84
169 Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2013 0.83
170 Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2011 0.83
171 The evolution of the conservative approach to breast cancer. Breast 2007 0.83
172 Primary and secondary angiosarcomas of the breast: a single institution experience. Breast Cancer Res Treat 2011 0.83
173 Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of Oncology. Ann Surg 2011 0.83
174 SP4, a novel anti-cyclin D1 rabbit monoclonal antibody, is a highly sensitive probe for identifying mantle cell lymphomas bearing the t(11;14)(q13;q32) translocation. Appl Immunohistochem Mol Morphol 2005 0.82
175 Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat 2011 0.82
176 Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat 2012 0.82
177 Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol 2003 0.82
178 Progesterone receptor immunoreactivity in minute meningothelioid nodules of the lung. Virchows Arch 2002 0.82
179 Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer. Anticancer Res 2009 0.82
180 Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol 2011 0.81
181 Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. Int J Cancer 2003 0.81
182 RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 2015 0.81
183 Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. Clin Cancer Res 2005 0.81
184 Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer 2010 0.81
185 Effectiveness of LigaSure diathermy coagulation in liver surgery. Surg Technol Int 2008 0.81
186 Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 2009 0.81
187 Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer 2012 0.81
188 Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. Virchows Arch 2011 0.81
189 Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 2011 0.80
190 Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. Virchows Arch 2005 0.80
191 Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer 2008 0.80
192 Clinical application of spectral electromagnetic interaction in breast cancer: diagnostic results of a pilot study. Tumori 2006 0.80
193 The classification of lung carcinoma: time to change the morphology-based approach? Int J Surg Pathol 2010 0.80
194 Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Mod Pathol 2004 0.79
195 CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 2015 0.79
196 Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer. Hum Pathol 2012 0.79
197 The TNM classification of breast cancer: need for change. Updates Surg 2010 0.79
198 Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. Breast 2007 0.79
199 Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. Oncologist 2009 0.79
200 A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. Virchows Arch 2005 0.79
201 Sensitivity of imaging for multifocal-multicentric breast carcinoma. BMC Cancer 2008 0.79
202 Underuse of anthracyclines in women with HER-2+ advanced breast cancer. Oncologist 2010 0.79
203 The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life. Breast Cancer Res Treat 2005 0.78
204 Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum Pathol 2003 0.78
205 A rare case of lung metastasis from a malignant adenomyoepithelioma of the breast: histological features and therapeutic implications. Ecancermedicalscience 2013 0.78
206 CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol 2004 0.78
207 Local therapy for breast cancer in malignant lymphoma survivors. Breast 2011 0.78
208 Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. Breast 2008 0.77
209 Effect of resection and outcome in patients with retroperitoneal sarcoma. ANZ J Surg 2006 0.77
210 Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. Breast Cancer Res Treat 2014 0.77
211 The sentinel node biopsy under local anesthesia in breast cancer: advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases. Breast 2007 0.77
212 Breast hamartoma: a case report. Breast Cancer Res Treat 2005 0.77
213 Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA. Breast Cancer Res Treat 2006 0.77
214 Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. Breast Cancer Res Treat 2013 0.77
215 Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. Int J Cancer 2004 0.77
216 Aggressive treatment approach for cloacogenic carcinoma of the anorectum: report from a single cancer center. Dig Surg 2010 0.77
217 Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach. Ecancermedicalscience 2013 0.77
218 Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. Br J Haematol 2003 0.77
219 Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunk. Ann Surg Oncol 2005 0.77
220 The Ligasure vessel sealer in liver resection: a pilot study. Hepatogastroenterology 2007 0.77
221 Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer 2005 0.76
222 HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. Appl Immunohistochem Mol Morphol 2016 0.76
223 Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. Breast 2010 0.76
224 A Trust-Based Pact in Research Biobanks. From Theory to Practice. Bioethics 2015 0.76
225 Breast cancer. Discov Med 2005 0.76
226 Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies. Curr Opin Oncol 2010 0.76
227 A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs 2006 0.76
228 Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. Virchows Arch 2005 0.76
229 Surgical treatment of advanced colorectal cancer in the elderly. Chir Ital 2005 0.76
230 Ultrasound-guided vacuum assisted breast biopsy in the assessment of C3 breast lesions by ultrasound-guided fine needle aspiration cytology: results and costs in comparison with surgery. Breast 2009 0.76
231 Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution. Ann Surg Oncol 2011 0.75
232 A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. Breast 2012 0.75
233 Re: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004 0.75
234 Identification of new hematopoietic cell subsets with a polyclonal antibody library specific for neglected proteins. PLoS One 2012 0.75
235 Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies. Appl Immunohistochem Mol Morphol 2015 0.75
236 Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. Breast 2006 0.75
237 Breast axillary lymph node metastasis. Int J Breast Cancer 2012 0.75
238 Ovarian serous papillary carcinoma, metastatic to intramammary lymph-node mimic a primary breast carcinoma on RX mammography. Breast J 2012 0.75
239 Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol 2017 0.75
240 Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases. Oncol Rep 2008 0.75
241 Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2015 0.75
242 Corrigendum: Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2015 0.75
243 A case of NUT midline carcinoma with no HPV infection, slight EWSR1 rearrangement and strong expression of EGFR. Tumori 2013 0.75
244 Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer. Breast 2010 0.75
245 Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. Acta Oncol 2015 0.75
246 Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nat Genet 2017 0.75
247 Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leuk Res 2008 0.75
248 Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol 2017 0.75
249 Tenascin-C in astrocytic tumors. Surg Neurol 2002 0.75
250 Adenomyoepithelioma of the breast, presenting as a cancer. Tumori 2004 0.75
251 Immunoreactivity for sex steroid hormone receptors in pulmonary hamartomas. Am J Surg Pathol 2006 0.75
252 Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors. J Thorac Oncol 2006 0.75